ORLANDO, Fla.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today reported the presentation of results from two clinical trials of VELCADE based combinations for the treatment of patients with previously untreated multiple myeloma (MM). An overall response rate (ORR) of 84 percent was observed in one study of VELCADE, cyclophosphamide and dexamethasone (VcCD) as induction therapy, and an ORR of 97 percent was observed in a study of VELCADE, lenalidomide, doxorubicin and dexamethasone (VcRDD). These data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held in Orlando, Florida, May 29 – June 2, 2009.
